Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Report Overview
Spinal muscular atrophy (SMA) is a group of inherited neuromuscular disorders. These disorders are clinically and genetically heterogeneous. The primary feature is the loss of lower motor neurons in the spinal cord. This results in progressive muscle weakness, muscle wasting, and low muscle tone. However, neurons controlling most voluntary muscles like those involved in feeding, swallowing, and breathing can also be affected.
| Key Mechanism of Action (Marketed) | · Protein or Peptide Activator
· Receptor Agonist |
| Key Routes of Administration (Marketed) | · Injection
· Oral · Enteral |
| Key Molecule Types (Marketed) | · Biologics
· Small Molecules · Oligonucleotides |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Spinal Muscular Atrophy (SMA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for spinal muscular atrophy (SMA). The report also analyzes the clinical and commercial landscapes of SMA, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
| Key Mechanisms of Action (Pipeline) | · Protein and Peptide Activator
· Biological Factor Inhibitor · Enzyme Inhibitor · Receptor Inhibitor · Receptor Modulator · Protein and Peptide Inhibitor · Receptor Antagonist · Ion Channel Blocker · Biological Factor Activator |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Enteral |
| Key Molecule Types (Pipeline) | · Biologics
· Small Molecules · Oligonucleotides |
| Top Sponsors (Marketed and Pipeline Drugs) | · F. Hoffmann-La Roche Ltd
· Biogen Inc · Novartis AG · Novartis Gene Therapies · Cytokinetics Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
SMA Marketed Drugs Segmentation by Mechanisms of Action
Most marketed drugs for SMA are protein or peptide activator followed by receptor agonist. Receptor agonists is approved only in Japan.
SMA Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of SMA Marketed Drugs
SMA Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for SMA marketed drugs are injection, oral, and enteral. Most marketed therapies have more than one route of administration. In 2023, most of the marketed drugs available for SMA are given by injection.
SMA Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of SMA Marketed Drugs
SMA Marketed Drugs Segmentation by Molecule Types
The key molecule types for SMA marketed drugs are biologics, small molecules, and oligonucleotides. Biologics and small molecules for SMA marketed drugs are equal in number.
SMA Marketed Drugs Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of SMA Marketed Drugs
SMA Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action for SMA pipeline drugs are protein and peptide activator, biological factor inhibitor, enzyme inhibitor, receptor inhibitor, receptor modulator, protein and peptide inhibitor, receptor antagonist, ion channel blocker, and biological factor activator. Protein and peptide activators make up the majority of the medications in the SMA pipeline in 2023.
SMA Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of SMA Pipeline Drugs
SMA Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration for SMA pipeline drugs are injection, oral, and enteral. Most pipeline drugs for SMA are injection therapies.
SMA Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of SMA Pipeline Drugs
SMA Pipeline Drugs Market Segmentation by Molecule Types
Most pipeline drugs for SMA are biologics, closely followed by small molecules. Oligonucleotide molecules in development are fewer in number and in earlier stages of development compared to the others.
SMA Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of SMA Pipeline Drugs
SMA Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the SMA marketed and pipeline drugs market are F. Hoffmann-La Roche Ltd, Biogen Inc, Novartis AG, Novartis Gene Therapies, and Cytokinetics Inc, among others. After calculating the total number of trial phases, F. Hoffmann-La Roche Ltd. emerged as the leading sponsor in 2023.
SMA Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for more sponsor insights into the SMA Marketed and Pipeline Drugs Market Download a Free Report Sample
Segments Covered in the Report
SMA Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Protein or Peptide Activator
- Receptor Agonist
SMA Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Enteral
SMA Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
- Oligonucleotides
SMA Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Protein and Peptide Activator
- Biological Factor Inhibitor
- Enzyme Inhibitor
- Receptor Inhibitor
- Receptor Modulator
- Protein and Peptide Inhibitor
- Receptor Antagonist
- Ion Channel Blocker
- Biological Factor Activator
SMA Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Enteral
SMA Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
- Oligonucleotides
Scope
Components of the report include –
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the SMA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SMA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for SMA marketed drugs?
In 2023, most of the marketed drugs for SMA are protein or peptide activators.
-
Which is the leading RoA for SMA marketed drugs?
In 2023, most of the marketed drugs for SMA are injection therapies.
-
Which is the leading MoA for SMA pipeline drugs?
In 2023, most of the SMA pipeline drugs are protein and peptide activators.
-
Which is the leading RoA for SMA pipeline drugs?
In 2023, most of the drugs in the SMA pipeline are injection therapies.
-
Which is the leading molecule type for SMA pipeline drugs?
In 2023, most of the pipeline drugs for SMA are biologics.
-
Who are the top sponsors for SMA marketed and pipeline drugs market?
Some of the top sponsors in the SMA marketed and pipeline drugs market are F. Hoffmann-La Roche Ltd, Biogen Inc, Novartis AG, Novartis Gene Therapies, and Cytokinetics Inc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Spinal Muscular Atrophy (SMA) reports